Solutions Accelerated by IsoPlexis
Cell & Gene Therapy
Apply PSI™ to CAR T-cell product release in a way that correlates to in vivo activity1
Detect the potent functional immune cell subsets that drive response and accelerate translational research.
Identify pre-infusion correlates to in vivo activity of cell therapy and patient outcome
IsoPlexis’ PSI is able to stratify responders and non-responders
Polyfunctional strength was found to correlate with objective response to CAR-T cell therapy, where other pre-infusion metrics did not
PSI of the pre-infusion CAR-T cell products showed significant correlation with the objective response of patients. The PSI, measured across a cohort of 20 patients, combined the CD4+ and CD8+ CAR-T response to CD19-K562 stimulation.
The average PSI of the responder subgroup was more than twice as high as the PSI of the non-responders, a difference that was shown to be statistically significant (p = 0.0119).1